Gilteritinib Improves Survival in AML with FLT3 Mutations


People with relapsed or refractory acute myeloid leukemia (AML) with FLT3 gene mutations treated with gilteritinib had improved survival, higher rates of remission, and fewer side effects than those treated with chemotherapy, a recent trial found.

Powered by WPeMatico